研究与报告
2026年9月14日•1 分钟阅读
Altheogen signs fourth ALT‑B4 licensing deal of 2024 with Novartis
Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.
研究与报告
2026年8月30日•1 分钟阅读
Targeted Therapies Transform Atopic Dermatitis Treatment
Emerging targeted drugs are shifting atopic dermatitis care from symptom control to broader quality‑of‑life improvements.